COMPARISON OF EFFICACY AND SAFETY OF ORMELOXIFENE AND CYCLICAL PROGESTERONE (NORETHISTERONE) IN OVULATORY ABNORMAL UTERINE BLEEDING

DIVYA VARDAINI¹, RAKESH MISHRA², RASHMI RANJAN³, SWAPNALI R BORADE⁴

¹Department of Pharmacology, World College of Medical Sciences and Research, Jhajjar, Haryana, India. ²Department of FMT, Veer Chandra Singh Garhwal Government Institute of Medical Science and Research, Srinagar, Uttarakhand, India. ³Department of PSM, World College of Medical Sciences and Research, Jhajjar, Haryana. Email: dvardaini@gmail.com

ABSTRACT

Objective: The objective of the study was to determine the efficacy and safety of ormeloxifene (ORM) versus norethisterone in controlling ovulatory abnormal uterine bleeding (AUB-O).

Methods: A prospective randomized comparative study of total 100 females of reproductive age in the age group 25–45 years with AUB-O. Patients were randomly divided in two groups of 50 each.

Results: ORM is more effective in reducing blood loss leading to improvement in mean hemoglobin and it also showed a higher ability to reduce endometrial thickness.

Conclusion: While both ORM and norethisterone are very effective drugs for AUB-O, ORM is safer, more cost-effective, non-steroidal, and non-hormonal drug with appropriate dosage and delivers better results for medical management of AUB-O. Therefore, ORM can be considered as the preferred drug in the management of AUB-O.

Keywords: Abnormal uterine bleeding, Ovulatory dysfunction, Endometrial hyperplasia, Ormeloxifene, Norethisterone, Selective estrogen receptor modulator, Hemoglobin, Heavy menstrual bleeding, Central nervous system.

INTRODUCTION

Menstrual disorders are the second most common gynecological conditions in hospital referrals. Abnormal uterine bleeding (AUB) includes all patterns of uterine bleeding that does not follow the normal menstrual pattern. AUB is an abnormality in volume, regularity, and/or timing lasting for 6 months. According to the classification given by FIGO (International Federation of Gynecology and Obstetrics), AUB-O is categorized in FIGO- system 2 [1]. It includes conditions such as polyp, adenomyosis, leiomyoma, malignancy, hyperplasia, coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, and those not yet classified. AUB-O can affect women from adolescence to perimenopausal years.

More and more women are looking forward for better and more convenient medical treatment. Even though there are a number of treatments available, a reliable drug for the management of AUB should meet requirements such as effectiveness, convenience, cost-effectiveness with minimal side effects, and long safety margin.

Approaches to medical management have been hindered by highly variable and non-evidence-based prescribing habits and lack of understanding of mechanisms causing AUB-O. The ideal treatment for AUB should be a designer drug which can block the action of estrogen on the endometrium; it is beneficial actions on the other tissues. Selective estrogen receptor modulators (SERMs) are one such class of drugs which have both agonistic and antagonistic actions on estrogen receptors [2]. They have varied tissue response which behaves as an estrogen antagonist in uterus and breast, being mildly agonist action on vagina, bone mineral density, central nervous system, and serum lipids, making it the perfect SERM for AUB-O. The current study was undertaken to the hypothesis that ormeloxifene (ORM) is superior to cyclical progesterone therapy in the treatment of pre-menopausal AUB-O [3].

MATERIALS

Place
The study was carried at the Department of Obstetrics and Gynaecology of Mata Chanan Devi Hospital, Janakpuri, New Delhi.

Study design
A prospective randomized comparative study.

Sample size
A total of 100 female patients were enrolled in this study. It was calculated keeping in view at the most 5% risk, with a minimum 80% power and 5% significance level.

Timeframe
March 2019 to December 2019

Inclusion criteria
Females in the reproductive age group, 25–45 years with AUB-O, were in the study.

Exclusion criteria
Women with
- Uterine pathology, for example, uterine polyp, leiomyoma, adenomyosis, and iatrogenic endometrial disorder
- Pelvic pathology and malignancies
- Systemic disorders
- Any history of thrombosis, bleeding disorder
- Severe anemia (<7 g)
- Pregnancy, abortion, ectopic, increased bleeding due to IUCDS
- Consistent use of oral contraceptive
- Hypersensitivity to the drug
- History of breast malignancy
Suspected adenomyosis
Current genital infection.

Methodology
The study was conducted after due approval of the Ethical Committee, Mata Chanan Devi Hospital, New Delhi. Patients were randomly divided in two groups of 50 each after taking informed consent from each patient who met the inclusion criteria. A thorough general and systemic examination was conducted before the study.

Patients enrolled in Group A received Tab ORM 60 mg twice a week, with a minimum gap of 3 days for 3 months. Likewise, patients enrolled in Group B received progesterone in the form of tablet 5 mg norethisterone twice a day for 21 days for 3 months starting from day 5 of the menstrual cycle. Hemoglobin (Hb) g% was evaluated and TVS was repeated for endometrial thickness (ET) in the proliferative phase (day 8–day 12 of the cycle) for each patient.

Statistical analysis
Quantitative variables are expressed in terms of mean ± SD and compared between groups using unpaired t-test and within groups across follow-ups using paired t-test. Qualitative variables are expressed in terms of frequencies/percentage and compared using Fisher’s exact test. The data were tabulated in MS Excel and analysis was performed using Statistical Package for the Social Science (SPSS) version 16.0 software.

Improvement in Hb and reduction in ET were compared in the pre-treatment period in both the study groups. The p value was considered statistically significant if <0.05.

RESULTS
Demographic characteristics
All subjects were of Indian origin from New Delhi, India. The mean ages were 40.56 and 39.76 for ORM and norethisterone study groups, respectively.

Mean Hb
The Hb levels were measured in both the study groups at regular intervals of time during the 3-months.

ET
The ET of the two study groups was measured at regular intervals.

Treatment outcomes
Ormeloxifene is more superior and effective than norethisterone and can be considered as the first line of treatment.

Effectiveness
Ormeloxifene was found to be more effective than norethisterone.

Safety
Ormeloxifene is safer than norethisterone.

DISCUSSION
This study was conducted in Mata Chanan Devi Hospital, New Delhi, India. One hundred patients were enrolled in this study. The patients were divided into two groups – 50 patients were enrolled in Group A who accepted ORM treatment and the rest 50 patients were enrolled in Group B who accepted norethisterone treatment. The mean age of the population was 40.56 years in ORM and 39.76 years in norethisterone group. The majority of women were multiparous. Socioeconomic status was found to be relatively higher in ORM group, but the difference was not statistically significant (p=0.055). Hence, both the groups were matched in age, parity, and socioeconomic status. Mean duration of symptoms was similar in both groups, that is, 25.32 months and 27.24 months in ORM and norethisterone groups, respectively. It was higher in norethisterone group, but the difference was not statistically significant (p=0.306).

Mean Hb at the time of presentation was 8.85 g% and 8.75 g% in ORM and norethisterone groups, respectively. Mean presenting Hb levels were comparable in both groups. Mean ET at the time of presentation was similar in both groups, that is, 11.94 mm and 11.83 mm in ORM and norethisterone groups, respectively.
Vardaini et al.

Asian J Pharm Clin Res, Vol 13, Issue 11, 2020, 178-180

Table 1: Mean age, parity, and duration of symptoms

|                | ORM Mean±SD | Norethisterone Mean±SD | p-value |
|----------------|-------------|-------------------------|---------|
| Age (years)    | 40.56±3.83  | 39.7±3.65               | 0.144   |
| Parity         | 2.46±0.81   | 2.30±0.54               | 0.125   |
| Duration of symptoms (months) | 25.32±18.75 | 27.2±19.02 | 0.306   |

ORM: Ormeloxifene

Table 2: Comparison of mean Hb (g%) between study groups

|            | ORM Mean±SD | Norethisterone Mean±SD | p-value | % Increase |
|------------|-------------|-------------------------|---------|------------|
| Hb         |             |                         |         |            |
| Pre-treatment | 11.68±0.83  | 11.83±0.74              | <0.001  | 32.40±6.28 |
| 3 months   | 10.54±0.74  | 9.56±0.65               | <0.001  | 20.80±7.1  |

Hb: Hemoglobin

Table 3: Distribution of ET between the two study groups over 3 months

|            | ORM Mean±SD | Norethisterone Mean±SD | p-value | % Decrease |
|------------|-------------|-------------------------|---------|------------|
| ET         |             |                         |         |            |
| Pre-treatment | 11.68±0.83  | 11.83±0.74              | <0.001  | 32.40±6.28 |
| 3 months   | 10.54±0.74  | 9.56±0.65               | <0.001  | 20.80±7.1  |

ET: Endometrial thickness

noretinesterone groups, respectively. ORM has been shown to be an effective and safe therapeutic option for the medical management of AUB. Chawla et al. [2], in their 2017 study, showed that use of centchroman (ORM) in conservative management of menorrhagia in premenopausal age group resulted in an increase of Hb level at the end of the study. Karmakar and Deshpande [3], in 2016, had done a study of efficacy and safety of ORM in a new treatment for DUB and the result was similar to our study. Jacob and Minl. [4] in their study in 2015, did a comparative study of both the drugs. Their result concluded that ORM is more effective than noretinesterone in the reduction of ET and rise in Hb. This, too, is similar to our study.

Furthermore, a 2018 study by Devi and Nimonkar [7] showed that there was a statistically significant increase in Hb and statistically significant decrease in ET with ORM. They, therefore, concluded that ORM is safe, cost-effective, non-steroidal, and non-hormonal drug with convenient doses and better compliance, which is similar to our study. It was found to be an excellent drug in controlling the system of AUB without affecting the normal endometrial and physiological parameters as a result that was similar to our study. Ravibabu et al. [8], in their 2013 study, showed that ORM was effective in reducing menstrual blood loss in patients in the treatment of AUB in all age groups with effective therapeutic efficacy and least side effects. They also concluded that the compliance of patients is good because of the convenient dosage schedule and no need of taking the drug every day.

CONCLUSION

AUB is the diagnosis in the majority of cases of HMB and accounts for a significant proportion of referrals to gynecologists. Both ORM and noretinesterone can be good alternatives to the medical and surgical treatment of HMB with good efficacy.

There was an improvement in mean Hb in both the groups in this study, ORM being more effective as compared to norethisterone. Mean Hb at baseline and 3rd month of treatment was found to be 8.85% and 11.68 g%, respectively, with ORM and 8.75% and 10.54%, respectively, with norethisterone. Improvement in Hb was statistically significant in both groups (p<0.001).

In addition, ORM is superior to norethisterone in its ability to reduce ET. There was a statistically significant reduction in mean ET with ORM (from 11.94 mm down to 8.08 mm) (p<0.001) and norethisterone (from 11.83 mm down to 9.56 mm).

For a treatment course of 3 months, ORM was found to be more cost-effective.

As both ORM and noretinesterone are very effective in reducing blood loss, they can be considered as first-line drugs in the management of AUB-0. Both are conservative modes of treatment and help to reduce the rate of hysterectomy and morbidity and associated mortality.

AUTHORS’ CONTRIBUTIONS

Dr Jasken Kaur, Consultant, Department of Obstetrics and Gynecology, MCDH, New Delhi, provided guidance in the preparation of the manuscript and reviewed it.

AUTHORS’ FUNDING

The study was funded by the Department of Obstetrics and Gynecology, Outpatient of Mata Chanan Devi Hospital, Janakpuri, New Delhi.

CONFLICTS OF INTEREST

The author declares no conflicts of interest.

REFERENCES

1. Munro MG, Critchley HO, Fraser IS, Hithotshwa R, Kriplani A, Bahamondes L, et al., FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynecol Obstet 2018;143:393-408.

2. Chawla SK, Bujha A, Sethi A, Puar NS, Paiwal V. Use of centchroman (saheli) in conservative management of menorrhagia: Our experience. Indian J Obstet Gynecol Res 2017;4:220-4.

3. Karmakar S, Deshpande H. Ormeloxifene—a new treatment modality in dysfunctional uterine bleeding: Efficacy and safety. Indian J Obstet Gynecol Res 2016;3:225-8.

4. Jacob JK, Mini DA. A comparative study on the effectiveness of ormeloxifene versus noretinesterone in the management of perimenopausal dysfunctional uterine bleeding. Int Arch Integ Med 2015;2:87-92.

5. Bhattacharyya TK, Anusuya B. Efficacy of a selective estrogen receptor modulator: Ormeloxifene in management of dysfunctional uterine bleeding. J South Asian Fed Obstet Gynaecol 2010;2:207-11.

6. Agrawal P, Shinde U, Shinde S, Aher G. Efficacy of ormeloxifene vs noretinesterone in the management of perimenopausal DUB. VIMSHSJ 2019;6:30-3.

7. Devi LT, Nimonkar R. Ormeloxifene in the management of dysfunctional uterine bleeding. Int J Reprod Contracept Obstet Gynecol 2018;7:1886.

8. Ravibabu K, Palla J, Chintada GS. A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. J Clin Diagn Res 2013;7:2534.